MedTrace Logo

A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy Volunteers

NCT01002963 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2010-10-25

No results posted yet for this study

Summary

The purpose of this study is to investigate safety and toleration of single oral doses as well as the time course of PF-04418948 concentration in the blood following dosing by oral solution.

Conditions

  • Healthy

Interventions

DRUG

PF-04418948

solution, 30 mg, single

DRUG

PF-04418948

solution, 100 mg, single

DRUG

PF-04418948

solution, 300 mg, single

DRUG

PF-04418948

solution, 1000 mg, single

DRUG

PF-04418948

solution, 3000 mg, single

DRUG

PF-04418948

solution, 4500 mg, single

DRUG

PF-04418948

solution, 6000 mg, single

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01002963 on ClinicalTrials.gov